Turn Therapeutics (TTRX) Cash & Equivalents (2024 - 2026)

Turn Therapeutics' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $11.2 million in Q1 2026; TTM through Mar 2026 was $11.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.1 million, up 918.72% from the prior year.
• Cash & Equivalents rose to $11.2 million in Q1 2026 per TTRX's latest filing, from $5.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.2 million in Q1 2026 and bottomed at $498286.0 in Q3 2024.
• The 3-year median for Cash & Equivalents is $3.1 million (2025), against an average of $4.1 million.
• Biggest YoY gain for Cash & Equivalents was 918.72% in 2025; the steepest drop was 523.37% in 2025.
• Year by year, Cash & Equivalents stood at $498286.0 in 2024, then surged by 918.72% to $5.1 million in 2025, then soared by 120.64% to $11.2 million in 2026.
• Per Business Quant, the three latest TTRX Cash & Equivalents figures stand at $11.2 million (Q1 2026), $5.1 million (Q4 2025), and $3.1 million (Q3 2025).